BioSavita is accelerating the development of biosimilar antibodies and offers a new expression system for better and faster production.
BioSavita licenses a yeast based antibody expression platform to biopharma for development and production of biosimilar cancer antibodies. Large pharma uses the platform as well as the company has expressed anti-cancer molecules. One program, anti-CD52 which is Campath offers a treatment for multiple sclerosis and leukemia. The company has 5 licensees and a pipeline of internally developed drugs. Strong management team and business model.